Left untreated, AL amyloidosis is associated with a very poor prognosis and < 1 year median survival in the presence of cardiomyopathy7, 8; however, chemotherapy directed at the underlying plasma cell dyscrasia can prolong median survival to beyond 3 years.9 Transthyretin amyloid cardiomyopathy (ATTR‐CM), caused by deposition of misfolded TTR protein in the heart, progresses slower than AL but is also fatal. This evidence concerns the gene TTR and AL amyloidosis.